REVIEW ON INTERNATIONAL COUNCIL FOR HARMONISATION GUIDELINE Q12

Mrs. Meenakshi. S. Mandavkar[1], Mr. Atharva R. Sankhe[2],
Miss. Srushti D. Raut[3], Mr. Varad D. Sangare[4]
[1]*Assistant Professor, VIVA Institute of Pharmacy, Virar*
[2,3,4]*Student, VIVA Institute of Pharmacy, Virar*

Abstract-**The pharmaceutical industry operates within a strictly regulated environment to ensure the effectiveness, safety, and quality of pharmaceutical products [9]. The International Council for Harmonization (ICH) Q12 guideline, titled "Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management," provides a structured framework for managing post-approval modifications efficiently and scientifically [4]. Introduced as a supplement to previous ICH guidelines (Q8–Q11), ICH Q12 enhances regulatory flexibility while maintaining rigorous product quality standards [3].**

A central component of ICH Q12 is the concept of Established Conditions (ECs), which define critical quality attributes and process parameters requiring regulatory oversight [13]. Additionally, the guideline introduces the Post-Approval Change Management Protocol (PACMP) to support manufacturers in implementing modifications more efficiently and predictably [12]. The Product Lifecycle Management (PLCM) Document further ensures consistency in managing product changes over time by promoting transparent communication with regulatory agencies [16].

The implementation of ICH Q12 varies across global regulatory bodies, and achieving harmonization remains challenging due to differences in regional regulatory expectations [11]. Despite these challenges, ICH Q12 represents a significant advancement in lifecycle management, enabling pharmaceutical companies to adopt continuous improvement strategies without compromising regulatory compliance [8]. This review provides a comprehensive analysis of ICH Q12, discussing its fundamental components, regulatory implications, practical challenges, and overall scope. Furthermore, the guideline's impact on international pharmaceutical operations and its potential to drive innovation while preserving product integrity are critically examined [15].

I. INTRODUCTION

The pharmaceutical industry operates under strict regulations to ensure the effectiveness, safety, and quality of pharmaceutical products. Over the years, global regulatory bodies have developed various standards to standardize and streamline the drug development, manufacturing, and post-approval processes. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) plays a vital role in this harmonization by establishing guidelines that align pharmaceutical regulations across different regions. To enhance regulatory flexibility and facilitate efficient pharmaceutical product lifecycle management, the ICH Q12 guideline, "Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management," was introduced [1,2].

Need for ICH Q12: Historically, complex and time-consuming regulatory frameworks have posed challenges for the pharmaceutical industry in implementing post-approval modifications. Under traditional regulatory systems, any change in a drug's composition, packaging, manufacturing process, or analytical techniques required extensive documentation and prior approval from regulatory authorities. This resulted in prolonged wait times, delaying the adoption of medical advancements that could improve product efficacy, cost-effectiveness, and quality [3,4]. The ICH Q12 guideline was developed to provide a systematic, scientific approach to post-approval change management. This framework introduces regulatory tools that grant manufacturers greater flexibility in implementing modifications while ensuring compliance with regulatory requirements and maintaining product quality. By enabling timely access to improved medications, ICH Q12 benefits both pharmaceutical companies and patients [5,6].

Evolution of ICH Guidelines Leading to ICH Q12:ICH Q8 (Pharmaceutical Development): Introduced the concept of Quality by Design (QbD), which emphasizes a systematic approach to drug formulation and process development [7].ICH Q9

(Quality Risk Management): Provided methodologies for assessing and mitigating risks in pharmaceutical quality management [8].ICH Q10 (Pharmaceutical Quality System): Established a lifecycle approach to pharmaceutical quality, integrating development, manufacturing, and continuous improvement [9].ICH Q11 (Development and Manufacture of Drug Substances): Outlined guidelines for the development and manufacturing of active pharmaceutical ingredients (APIs), including process controls and regulatory expectations [10].While these guidelines primarily focus on pharmaceutical development and manufacturing, they lack a comprehensive framework for post-approval lifecycle management. The absence of globally harmonized regulatory measures for handling post-approval modifications has resulted in regional inconsistencies, increasing regulatory burden on authorities and the pharmaceutical industry. To address this gap, ICH Q12 was developed, offering a standardized, risk-based approach to managing post-approval changes. This guideline integrates with existing regulatory frameworks while introducing additional tools to support flexible, transparent, and science-driven regulatory decision-making [11,12].

II. SCOPE OF ICH Q12

The "Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management" (ICH Q12) guideline provides a structured framework for managing modifications to pharmaceutical products post-approval. The guideline applies to both chemical and biological medicinal products, including active pharmaceutical ingredients (APIs). Additionally, it considers drug-device combination products when relevant [1,2].

The primary scope of ICH Q12 includes:

Pharmaceutical Lifecycle Management: Establishes a systematic approach to efficiently managing post-approval modifications, fostering innovation and continuous improvement in pharmaceutical manufacturing [3,4].

Regulatory Harmonization: Provides a globally standardized framework for regulatory agencies such as the FDA, EMA, and PMDA to streamline post-approval change processes. It aims to reduce regional regulatory disparities, leading to faster and more predictable approvals [5,6].

Application to Diverse Pharmaceutical Products: Encompasses both new and existing biological and chemical entities, including small molecules, biologics, and specific drug-device combination products [7].

Established Conditions (ECs): Defines critical product and manufacturing process parameters that require regulatory approval before modifications. This ensures that non-essential changes can be implemented with minimal regulatory oversight [8].

Post-Approval Change Management Protocol (PACMP): Introduces a structured approach with pre-approved regulatory pathways for handling future modifications, allowing flexibility while maintaining product quality and compliance [9].

Product Lifecycle Management (PLCM) Document: Serves as a comprehensive record of the product's manufacturing and regulatory history, facilitating transparent communication between regulatory authorities and manufacturers [10].

Integration with Existing ICH Guidelines: Builds upon previous ICH guidelines, including ICH Q8 (Pharmaceutical Development), ICH Q9 (Quality Risk Management), ICH Q10 (Pharmaceutical Quality System), and ICH Q11 (Development and Manufacture of Drug Substances). It extends risk-based principles to enhance regulatory flexibility [11,12].

III. OBJECTIVES OF ICH Q12

The primary objectives of ICH Q12 include:

Enhancing Regulatory Flexibility: Establish a risk- and science-based approach to managing post-approval modifications. Reduce unnecessary regulatory submissions and approval delays [1,2].

Encouraging Lifecycle Management: Support manufacturers in continuously improving their products while maintaining quality. Promote a proactive approach to managing product and process modifications [3,4].

Clarifying Established Conditions (ECs): Define the key aspects of a pharmaceutical product that require regulatory oversight. Enable minor adjustments to be implemented with minimal regulatory burden [5].

Introducing the Post-Approval Change Management Protocol (PACMP): Improve the efficiency of regulatory submissions and approvals. Allow manufacturers to obtain regulatory agreement on anticipated changes in advance [6].

Developing a Product Lifecycle Management (PLCM) Document: Assist industry stakeholders and regulators in tracking product changes over time. This document should provide a structured

record of post-approval modifications to enhance regulatory transparency [7].

Harmonizing Post-Approval Modifications Globally: Reduce regional discrepancies in regulatory requirements. Establish a standardized approach for regulatory agencies and industry worldwide [8,9].

Promoting Risk-Based Decision-Making: Incorporate the principles of Quality Risk Management (QRM) and Quality by Design (QbD) in lifecycle management. Allow flexibility for non-critical modifications while ensuring regulatory oversight on key quality attributes [10,11].

IV. KEY ELEMENTS OF ICH Q12

ICH Q12 introduces principles and regulatory mechanisms to enhance post-approval change management in pharmaceutical products. These components establish a structured, scientifically justified approach, ensuring product quality while allowing flexibility in implementing changes [1].

1)Established Conditions (ECs)

Definition: Established Conditions (ECs) are legally binding elements of a pharmaceutical product or its manufacturing process that require regulatory approval before modifications [2].

Key Attributes: ECs define specific aspects of a product and process that must be regulated. They distinguish critical from non-critical changes, streamlining regulatory evaluations and allowing internal management of non-EC changes without requiring regulatory filings [3].

Examples:

Drug Substance: Factors influencing stability, purity, and bioavailability [4].

Drug Product: Ingredients, dosage form, and key manufacturing processes [5].

Analytical Methods: Essential testing procedures, specifications, and acceptance criteria [6].

Advantages: ECs enhance operational efficiency by reducing unnecessary regulatory submissions for minor changes while ensuring that regulatory focus remains on quality-impacting modifications [7].

2)Post-Approval Change Management Protocol (PACMP)

Definition: PACMP is a pre-approved regulatory strategy that facilitates planning and execution of post-approval changes [8].

Key Attributes: PACMP offers a structured mechanism for regulatory agencies to assess and pre-approve changes before implementation. It enables manufacturers to execute pre-agreed modifications without resubmitting a full variation application, thereby increasing transparency and predictability in change management [9].

Examples:

Change of Manufacturing Site: Pre-approved facility additions or improvements [10].

Process Optimization: Implementation of enhanced production techniques [11].

Analytical Method Changes: Adoption of validated, modern analytical technologies [12].

Advantages: PACMP accelerates approval timelines for planned modifications, facilitating faster improvements in manufacturing and product quality [13].

3)Product Lifecycle Management (PLCM) Documentation

Definition: The PLCM document serves as a comprehensive record of a product's regulatory and manufacturing history, fostering transparency between industry and regulators [14].

Key Attributes: This document provides a centralized reference for tracking post-approval changes throughout a product's lifecycle. It includes details on anticipated modifications, regulatory commitments, and ECs, aiding continuous improvement and regulatory decision-making [15].

Advantages: PLCM documentation improves regulatory efficiency by reducing unnecessary delays and facilitating more effective post-approval change assessments [16].

4)Classification of Post-Approval Modifications

Definition: ICH Q12 introduces a risk-based classification system to determine the level of regulatory oversight required for post-approval changes [4].

Key Categories:

Major Changes: Require full regulatory review and approval due to significant impact on product quality (e.g., changes in active pharmaceutical ingredient synthesis affecting stability) [7].

Moderate Changes: Require regulatory notification but not full approval; these have moderate quality impact (e.g., switching an excipient supplier with minor formulation effects) [9].

Minor Changes: Can be implemented without prior regulatory approval as they have minimal or no quality impact (e.g., batch size modifications within approved limits) [11].

Advantages: This classification system expedites low-risk modifications, reducing regulatory burdens and improving manufacturing agility [13].

5)Regulatory Tools and Enablers

Definition: ICH Q12 incorporates additional regulatory tools to facilitate and standardize post-approval change management [15].

Key Tools:

Quality Risk Management (QRM): Aligns with ICH Q9 to assess and mitigate risks, ensuring regulatory focus on changes affecting critical quality attributes (CQAs) [16].

Knowledge Management (KM): Utilizes scientific knowledge and historical data to justify post-approval changes, streamlining regulatory submissions [17].

Advantages: These tools enable data-driven decision-making and risk-based regulatory oversight, reducing unnecessary regulatory delays [14].

6)Integration with Other ICH Guidelines

ICH Q12 complements existing ICH guidelines to create a holistic pharmaceutical lifecycle management framework [12].

Relevant Guidelines:

ICH Q8: Establishes Quality by Design (QbD) principles [5].

ICH Q9: Provides a risk management framework [6].

ICH Q10: Adopts a lifecycle approach to product quality [8].

ICH Q11: Focuses on API development and manufacturing [10].

Advantages: This integration ensures a scientifically sound, comprehensive regulatory approach for pharmaceutical products [13].

V. IMPLEMENTATION OF ICH Q12

The International Council for Harmonisation (ICH) Q12 guideline provides a structured, risk-based approach to managing post-approval changes in pharmaceuticals. The successful implementation of this guideline necessitates collaboration between regulatory authorities and industry stakeholders to establish effective lifecycle management while ensuring product quality and compliance. This guideline aims to streamline regulatory processes, offer flexibility, and promote continuous improvement in pharmaceutical manufacturing [1,2].

1)Establishment of Established Conditions (ECs): The concept of Established Conditions (ECs) plays a crucial role in the implementation of ICH Q12. Pharmaceutical companies must define ECs and provide appropriate justification in their regulatory submissions. These ECs should be explicitly documented in the Common Technical Document (CTD) format to ensure compliance with regulatory expectations. Manufacturers must identify which aspects of their process and product require regulatory oversight before implementing any modifications [3,4]. Changes to these conditions should not proceed without prior regulatory approval, ensuring that product quality and efficacy remain uncompromised [5].

2)Development of Product Lifecycle Management (PLCM) Document: PLCM document serves as a vital tool for maintaining regulatory commitments and tracking product changes. It documents ECs, outlines proposed post-approval modifications, and facilitates communication between industry and regulatory agencies [6,7]. By maintaining an up-to-date PLCM document, pharmaceutical companies enhance transparency in lifecycle management, enabling regulators to assess changes more effectively and efficiently [8,9].

3)Implementation of Post-Approval Change Management Protocol (PACMP): The PACMP framework provides a structured approach for managing post-approval changes by allowing predefined modifications without requiring new regulatory applications. By submitting a PACMP in advance, companies can gain regulatory approval for specific changes, enhancing predictability and efficiency in post-approval change management [10,11]. This proactive approach minimizes delays and ensures that changes are implemented while maintaining product quality and compliance [12,13].

4)Integration with Pharmaceutical Quality System (PQS) and Quality Risk Management (QRM): To fully integrate ICH Q12, companies must align their quality systems with ICH Q10 (Pharmaceutical Quality System) and ICH Q9 (Quality Risk Management) [14]. Risk assessments should be conducted to evaluate the potential impact of proposed modifications on product quality, facilitating informed decision-making [15]. QRM principles enable companies to handle non-critical changes internally with minimal regulatory

oversight, thereby optimizing the efficiency of the change management process [16,17].

5)Global Regulatory Submission Strategy: The implementation of ICH Q12 requires harmonization across multiple regulatory agencies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA). Pharmaceutical manufacturers must develop regional strategies tailored to specific regulatory requirements to ensure compliance in different jurisdictions [4,6]. By standardizing regulatory approaches, companies can reduce compliance burdens and enhance flexibility within global supply chains [9,13]. A well-defined regulatory strategy fosters consistency in managing post-approval changes, supporting efficient and timely modifications without compromising regulatory expectations [12,15].

In conclusion, the successful implementation of ICH Q12 necessitates a comprehensive strategy encompassing ECs, PLCM documentation, PACMP frameworks, PQS integration, and global regulatory harmonization. By adhering to these principles, pharmaceutical manufacturers can enhance regulatory efficiency, promote continuous improvement, and ensure robust product lifecycle management while maintaining the highest standards of quality and compliance.

VI. REGULATORY IMPACT OF ICH Q12

The implementation of ICH Q12 significantly influences industry operations, approval procedures, and regulatory frameworks. This guideline aims to streamline regulatory processes while promoting pharmaceutical innovation and supply chain flexibility [1].

Harmonization of International Regulations: ICH Q12 facilitates the standardization of post-approval modifications, thereby reducing regulatory discrepancies across different jurisdictions [2]. This harmonization enables mutual recognition of regulatory approvals, reducing the need for redundant submissions in multiple regions [3]. For instance, a modification approved by the U.S. Food and Drug Administration (FDA) may be more readily accepted by the European Medicines Agency (EMA) or the Pharmaceuticals and Medical Devices Agency (PMDA), thus enhancing global market access [4].

Enhanced Regulatory Effectiveness: By defining Established Conditions (ECs) and Post-Approval Change Management Protocols (PACMPs), ICH Q12 allows regulatory authorities to focus primarily on significant changes, while companies can self-manage non-critical modifications [5]. This reduces the regulatory burden and optimizes resource allocation, allowing agencies to prioritize innovative and high-risk pharmaceutical products [6].

Expedited Post-Approval Modifications: Under traditional regulatory frameworks, companies are often required to submit full variation applications for most modifications. However, ICH Q12 permits numerous non-essential adjustments without prior regulatory approval, leading to fewer supply chain disruptions and quicker implementation of product modifications [7,8].

Promotion of Innovation and Continuous Manufacturing: The reduction of regulatory obstacles fosters the adoption of new technologies, process automation, and continuous manufacturing practices [9]. By integrating digital advancements and innovative production methodologies, pharmaceutical manufacturers can enhance flexibility while maintaining stringent quality standards [10,11]

Impact on the Pharmaceutical Supply Chain: ICH Q12 introduces greater adaptability within the pharmaceutical supply chain by enabling companies to switch manufacturers or suppliers more efficiently [12]. This flexibility minimizes the risk of drug shortages and allows prompt responses to supply chain disruptions [13]. For example, if an excipient supplier faces quality issues, manufacturers can transition to an alternative supplier without substantial regulatory delays [14].

Enhancement of Quality Risk Management (QRM): The implementation of ICH Q12 strengthens risk-based regulatory oversight by ensuring that only significant changes undergo rigorous evaluation [15]. The guideline aligns with ICH Q9 on Quality Risk Management (QRM) and ICH Q10 on the Pharmaceutical Quality System, thereby reinforcing manufacturing robustness and overall regulatory compliance [16,17].

VII. CHALLENGES IN IMPLEMENTING ICH Q12

The implementation of ICH Q12 presents several challenges that must be addressed for its successful adoption across the pharmaceutical industry. While the guideline provides a structured framework for post-approval change management, various technical, regulatory, and industry-related hurdles

must be overcome to ensure its effective execution. Collaboration between pharmaceutical companies, regulatory agencies, and industry stakeholders is essential to mitigate these challenges.One significant challenge is the issue of global regulatory acceptance and harmonization. Regulatory authorities across different regions adopt ICH Q12 at varying rates, leading to inconsistencies in approval criteria and post-approval change management, which hampers global implementation efforts [1,4,6]. Additionally, disparities in the interpretation of established conditions (ECs) pose difficulties for pharmaceutical companies. Different regulatory bodies may define and evaluate ECs in varying ways, resulting in ambiguity during submission preparation [4,7].The lack of mutual recognition for post-approval changes is another concern. In the absence of mutual recognition agreements (MRAs), companies must submit multiple applications for the same modification across different regulatory jurisdictions, significantly increasing the administrative burden [5,10]. Furthermore, the complexity in defining and managing Post-Approval Change Management Protocols (PACMPs) adds another layer of difficulty. Regional variations in PACMP implementation limit the intended flexibility and efficiency of the guideline [12,16].Another challenge is the integration of ICH Q12 with existing pharmaceutical quality systems (PQS). Aligning this framework with ICH Q9 (Quality Risk Management) and ICH Q10 (Pharmaceutical Quality System) requires substantial financial investment and process modifications, making implementation burdensome, particularly for resource-constrained companies [8,14]. Moreover, regulatory uncertainty and risk aversion can hinder progress. Some agencies may prefer a more conservative approach, demanding additional information or full variation applications instead of leveraging the streamlined ICH Q12 processes [9,11].Resistance to change from conventional regulatory methods is another critical barrier. Industry professionals and regulators accustomed to traditional post-approval change management may be hesitant to fully adopt ICH Q12 principles, further slowing implementation [10,15]. Additionally, the increased documentation burden and data requirements present challenges. Justifying ECs and PACMPs often necessitates extensive data generation, leading to additional workload for regulatory affairs teams and potential delays in approvals [6,13].Small and medium-sized enterprises (SMEs) face significant compliance difficulties. Unlike larger pharmaceutical corporations, SMEs may struggle to meet the financial and resource demands necessary for ICH Q12 adoption, making the guideline's implementation disproportionately challenging for them [3,7]. Lastly, the time required for complete execution should not be underestimated. Transitioning to a new lifecycle management approach demands extensive adaptation by both businesses and regulatory agencies, which can prolong the shift from traditional frameworks to ICH Q12-based systems [2,16].Addressing these challenges requires a concerted effort from all stakeholders involved. Regulatory agencies must work towards global harmonization, while pharmaceutical companies need to allocate appropriate resources to ensure smooth integration of ICH Q12 principles. By overcoming these barriers, the industry can achieve a more efficient and globally harmonized approach to pharmaceutical lifecycle management.

VIII. FUTURE PROSPECTS FOR ICH Q12

ICH Q12 has introduced a revolutionary approach to post-approval change management, aiming to streamline regulatory processes while maintaining product quality. The future of ICH Q12 appears promising, contingent on continued adaptation by pharmaceutical companies and global regulatory agencies. However, further progress is necessary in harmonization, technological integration, and widespread industry adoption.

Global Harmonization and Adoption: It is expected that an increasing number of regulatory authorities worldwide will adopt ICH Q12, thereby facilitating international drug approvals and minimizing inconsistencies in post-approval change management [4,6,10].

Standardization of Established Conditions (ECs) and Post-Approval Change Management Protocols (PACMPs): Future regulatory guidelines are anticipated to provide clearer definitions and uniform methodologies for ECs and PACMPs, ensuring more predictable regulatory assessments and streamlined post-approval change procedures [12,15].

Integration of AI-Powered and Digital Regulatory Tools: The incorporation of AI-driven decision-making, risk assessments, and automated electronic submissions is expected to improve

regulatory review efficiency and approval timelines, reducing manual workload and enhancing decision accuracy [5,13,16].

Alignment with Pharmaceutical Quality Systems (PQS): ICH Q12 is likely to be further integrated with ICH Q9 (Quality Risk Management) and ICH Q10 (Pharmaceutical Quality System) to promote a risk-based, science-driven approach to change management, ensuring robust regulatory compliance [3,7,9].

Enhanced Industry-Regulator Collaboration: More interactive discussions, pilot projects, and accelerated approval pathways will foster smoother implementation of ICH Q12 principles, strengthening regulatory-industry partnerships and enhancing mutual understanding [10,14].

Increased Supply Chain Flexibility: With faster adaptation to changes in suppliers and manufacturing sites, global drug availability will improve, mitigating shortages and granting pharmaceutical companies greater flexibility to meet dynamic market demands [8,14,17].

Extension to Emerging Therapies: ICH Q12 principles may extend to address the unique regulatory challenges posed by advanced therapies, including biologics, cell and gene therapies, and personalized medicine, ensuring their safe and efficient lifecycle management [2,15].

Technological Advancements in Lifecycle Management: The adoption of blockchain for secure documentation, cloud-based regulatory systems, and automated tracking technologies is projected to enhance post-approval change management, improving transparency and traceability [6,11,14].

Strengthening Regulatory Education Programs: To ensure consistent application and compliance with ICH Q12, additional training programs for industry professionals and regulators will be implemented, facilitating knowledge dissemination and harmonized adoption [9,12,16].

Continuous Improvement and Policy Reforms: Future refinements to ICH Q12 will focus on adapting regulatory pathways to evolving pharmaceutical industry needs, optimizing lifecycle management efficiency, and fostering innovation in regulatory strategies [1,3,17].

By addressing these aspects, the future of ICH Q12 will significantly contribute to a more efficient, globally harmonized regulatory landscape, ultimately benefiting patients and the pharmaceutical industry alike.

IX. CONCLUSION

The introduction of a standardized framework for post-approval change management through ICH Q12 represents a significant advancement in pharmaceutical regulatory science [1,2]. By shifting from a rigid, approval-driven system to a risk-based, science-driven approach, ICH Q12 aims to enhance regulatory flexibility while ensuring product quality, safety, and efficacy [3,4]. Despite its advantages, successful implementation requires addressing challenges such as inconsistent global regulations, varying interpretations of Established Conditions (ECs), and industry adaptation hurdles [5,6]. While some regulatory agencies have begun incorporating ICH Q12, achieving full harmonization necessitates further collaboration among pharmaceutical companies, regulators, and industry stakeholders [7,8].The future of ICH Q12 appears promising, with increasing global adoption, integration of digital technologies, AI-driven regulatory evaluations, and advancements in lifecycle management practices [9,10]. The application of ICH Q12 principles to biologics, gene therapies, and other innovative pharmaceuticals could further streamline regulatory processes and enhance the efficiency of modern drug development [11,12]. However, to fully realize its potential, continuous training, regulatory capacity-building, and policy refinements are essential [13,14].Timely, transparent, and scientifically robust implementation of post-approval modifications will be greatly facilitated by ICH Q12, fostering a more flexible and internationally harmonized regulatory framework [15,16]. As technological advancements progress and regulatory authorities, industry leaders, and stakeholders remain committed to its principles, ICH Q12 will ultimately contribute to improved patient outcomes and a more efficient healthcare system [17].

REFERENCES

[1]. Kibbe AH. Handbook of pharmaceutical excipients. 4th ed. London: Pharmaceutical Press; 2000.

[2]. Shah VP, Midha KK. Pharmaceutical product development: In vitro–in vivo correlation. Springer; 2015.

[3]. Gupta A, Kulkarni R. ICH guidelines: Quality, safety, and efficacy. Pharma Publications; 2022.

[4]. International Council for Harmonisation (ICH). ICH Q12 guideline: Step 4. 2019.

Available from: https://database.ich.org/sites/default/files/Q12_Guideline_Step4_2019_1119.pdf

[5]. U.S. Food and Drug Administration (FDA). Guidance on ICH Q12. 2021. Available from: https://www.fda.gov/media/148947/download

[6]. European Medicines Agency (EMA). ICH Q12 technical and regulatory considerations for pharmaceutical product lifecycle management. 2020. Available from: https://www.ema.europa.eu/en/ich-q12-technical-regulatory-considerations-pharmaceutical-product-lifecycle-management-scientific-guideline

[7]. Niazi SK. Handbook of pharmaceutical manufacturing formulations: Regulatory issues. 2nd ed. CRC Press; 2019.

[8]. Willig SH, Stoker JR, Tuckerman MM. Good manufacturing practices for pharmaceuticals. 6th ed. Informa Healthcare; 2001.

[9]. Khan M, Smarta RB. Pharmaceutical regulatory affairs: Current issues and future challenges. Business Expert Press; 2020.

[10]. International Society for Pharmaceutical Engineering (ISPE). Vision for ICH Q12: Current experience and future direction. 2021. Available from: https://ispe.org/pharmaceutical-engineering/september-october-2021/vision-ich-q12-current-experience-future

[11]. Regulatory Affairs Professionals Society (RAPS). ICH developments and updates. 2021. Available from: https://www.raps.org/news-and-articles/news-articles/2021/5/ich

[12]. CASSS. ICH Q12: Global implementation challenges with PACMPs and established conditions. 2024. Available from: https://www.casss.org/docs/default-source/wcbp/2024-roundtable-notes/ich-q12--global-implementation-challenges-with-pacmps-and-established-conditions.pdf

[13]. Freyr Solutions. ICH Q12: Transforming global regulatory post-approval submissions. 2022. Available from: https://www.freyrsolutions.com/blog/ich-q12-transforming-global-regulatory-post-approval-submissions

[14]. Hussain AS, Smith RL. Continuous manufacturing of pharmaceuticals. Wiley; 2020.

[15]. Blanchard J, Rigdway K. Pharmaceutical lifecycle management: Making the most of ICH Q12. Springer; 2021.

[16]. BioPhorum. Industry feedback on ICH Q12 implementation considerations for FDA-regulated products. 2021. Available from: https://www.biophorum.com/download/industry-feedback-on-ich-q12-implementation-considerations-for-fda-regulated-products/

[17]. CASSS. Regulatory considerations for ICH Q12 implementation. 2021. Available from: https://www.casss.org/docs/default-source/cmc-strategy-forum-north-america/2021-cmc-na-speaker-presentations/ramanadham-mahesh-cder-fda-2021.pdf?sfvrsn=d8b6c041_8